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Objectives
To review the measurement methods of radiological
‘tumour response’ in two clinical trials.
Methods
Neo-tAnGo and ARTemis are national 800-patient breast
cancer trials assessing neo-adjuvant chemotherapy regi-
mens, both with a secondary endpoint of radiological
tumour response, assessing treatment effect in terms of
change in tumour size. Both trials record radiological
sizes at baseline, mid-way through and at the end of the
chemotherapy regimens.
Neo-tAnGo (randomising Jan’05 to Sept’07) recorded
mammograms and/or ultrasounds and/or MRI scans,
identifying up to two breast and one axillary lesion as
‘target’ lesions. At each of the 3 time-points and for
each target lesion, the scan types and largest diameters
observed (maximum of two) were reported, along with a
clinical judgement of response.
ARTemis (randomising May’09 to Jan’13) recorded
ultrasounds only, recording the longest single diameter
of each tumour (including axillary tumours) along with
total ‘tumour bulk’ in each breast. At mid- and end-
chemotherapy, a clinical judgement of response per
breast is also recorded.
Results
In neo-tAnGo, the type of radiological scan used and
number of recorded dimensions varied, not only across
hospitals but also within-hospitals across patients and
across assessment times, creating challenges regarding
tumour comparisons. In ARTemis, difficulties existed
surrounding the clinical response categorisation and
interpretation of ‘tumour bulk’, and non-adherence to
the specified radiological technique raised methodologi-
cal issues.
Conclusions
Optimally recording radiological ‘tumour response’ and
making meaningful inter-patient, inter-tumour or inter-
time-point comparisons is challenging. Specifications
regarding the authorised radiological scanning techni-
ques and reporting of findings are imperative in a trial
protocol.
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